Sulfamethoxazole drug stress upregulates antioxidant immunomodulatory metabolites in Escherichia coli

• Published in: Nature microbiology Vol. 5; no. 11; pp. 1319 - 1329
• Main Authors: Park, Hyun Bong, Wei, Zheng, Oh, Joonseok, Xu, Hao, Kim, Chung Sub, Wang, Rurun, Wyche, Thomas P., Piizzi, Grazia, Flavell, Richard A., Crawford, Jason M.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.11.2020; Nature Publishing Group
• Subjects: 13/106; 13/31; 38/77; 631/326/2565/2134; 631/92/349; 64/60; Amino acids; Animal models; Animals; Antioxidants; Antioxidants - administration & dosage; Antioxidants - chemistry; Antioxidants - metabolism; Antioxidants - pharmacology; Biomedical and Life Sciences; Cells, Cultured; Colitis; Colitis - drug therapy; Colitis - microbiology; Disease Models, Animal; E coli; Escherichia coli; Escherichia coli - genetics; Escherichia coli - metabolism; Escherichia coli - physiology; Escherichia coli Proteins - genetics; Escherichia coli Proteins - metabolism; Gastrointestinal Microbiome; Gastrointestinal tract; Humans; Immunology; Immunomodulation; Infectious Diseases; Inflammatory bowel disease; Inflammatory bowel diseases; Interleukin 10; Interleukin-10 - metabolism; Intestine; Letter; Life Sciences; Medical Microbiology; Metabolic Networks and Pathways; Metabolic pathways; Metabolism; Metabolites; Mice; Microbiology; Oxidation-Reduction; Parasitology; Phenotypes; Probiotics; Pteridines - administration & dosage; Pteridines - chemistry; Pteridines - metabolism; Pteridines - pharmacology; Stress, Physiological; Sulfamethoxazole; Sulfamethoxazole - administration & dosage; Sulfamethoxazole - metabolism; Virology
• ISSN: 2058-5276; 2058-5276
• DOI: 10.1038/s41564-020-0763-4

Escherichia coli is an important model organism in microbiology and a prominent member of the human microbiota 1 . Environmental isolates readily colonize the gastrointestinal tract of humans and other animals, and they can serve diverse probiotic, commensal and pathogenic roles in the host 2 – 4 . Although certain strains have been associated with the severity of inflammatory bowel disease (IBD) 2 , 5 , the diverse immunomodulatory phenotypes remain largely unknown at the molecular level. Here, we decode a previously unknown E. coli metabolic pathway that produces a family of hybrid pterin–phenylpyruvate conjugates, which we named the colipterins. The metabolites are upregulated by subinhibitory levels of the antifolate sulfamethoxazole, which is used to treat infections including in patients with IBD 6 , 7 . The genes folX/M and aspC/tyrB involved in monapterin biosynthesis 8 – 10 and aromatic amino acid transamination, 11 respectively, were required to initiate the colipterin pathway. We show that the colipterins are antioxidants, harbour diverse immunological activities in primary human tissues, activate anti-inflammatory interleukin-10 and improve colitis symptoms in a colitis mouse model. Our study defines an antifolate stress response in E. coli and links its associated metabolites to a major immunological marker of IBD. Subinhibitory levels of sulfamethoxazole, an antibiotic used to treat Escherichia coli infections, trigger a previously undescribed metabolic pathway in E. coli that comprises a family of hybrid pterin–phenylpyruvate conjugates called colipterins. These metabolites are antioxidants, have immunomodulatory properties and improve colitis in a murine model.